Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles

Executive Summary

Sponsors and FDA also will have to work through issues related to companion diagnostics to prevent treatments designated under the FDASIA’s new expedited development pathway from being delayed. Harmonization with foreign regulators is essential to making the pathway work, stakeholders say.

You may also be interested in...



When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes

Clinical data supporting a designation request should come from a product under development, not from a study using an earlier formulation, CBER reps say. Rolling submissions help ensure that potential manufacturing and facility concerns are identified early.

FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products

FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.

FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products

FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel